Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10595260 | Bioorganic & Medicinal Chemistry Letters | 2012 | 5 Pages |
Abstract
This Letter describes the continued optimization of an MLPCN probe molecule (ML012) through an iterative parallel synthesis approach. After exploring extensive modifications throughout the parent structure, we arrived at a more highly M1-selective antagonist, compound 13l (VU0415248). Muscarinic subtype selectivity across all five human and rat receptors for 13l, along with rat selectivity for the lead compound (ML012), is presented.
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Bruce J. Melancon, Alexander P. Lamers, Thomas M. Bridges, Gary A. Sulikowski, Thomas J. Utley, Douglas J. Sheffler, Meredith J. Noetzel, Ryan D. Morrison, J. Scott Daniels, Colleen M. Niswender, Carrie K. Jones, P. Jeffrey Conn, Craig W. Lindsley,